Cadrenal Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(a) Unregistered Sales of Equity Securities
We did not sell any equity securities during the quarter ended September 30, 2024 and up to the date of the filing of this Quarterly Report on Form 10-Q in transactions that were not registered under the Securities Act other than as set forth below and as previously disclosed in our filings with the SEC.
On September 11, 2024, we issued 13,333 shares of restricted common stock to a consultant as partial compensation for services.
On October 10, 2024, we issued 25,000 shares of restricted common stock to a consultant as partial compensation for services.
(b) Use of Proceeds
(c) Issuer Purchases of Equity Securities
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.